Ermium Therapeutics is a startup based in France.
Ermium Therapeutics was a biotech company developing functionally selective immunomodulators targeting CXCR4 for autoimmune disease indications, particularly interferonopathies including systemic lupus erythematosus (SLE). The company ceased operations in 2024.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.